Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Nucana ( (NCNA) ).
On June 18, 2025, NuCana plc announced that its CEO, Hugh S. Griffith, will take a leave of absence due to health reasons, with Andrew Kay stepping in as Executive Chairman and Ian Webster as Interim CFO. Additionally, the company faces potential delisting from the Nasdaq Capital Market due to concerns over its recent May 2025 offering, which could negatively impact its ability to raise capital and the liquidity of its shares.
The most recent analyst rating on (NCNA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a company operating in the biopharmaceutical industry, primarily focused on developing new cancer treatments. The company is known for its innovative approach to chemotherapy, aiming to improve the efficacy and safety of cancer drugs.
Average Trading Volume: 135,106,728
Technical Sentiment Signal: Sell
Current Market Cap: $794.7K
Find detailed analytics on NCNA stock on TipRanks’ Stock Analysis page.